Harvesting  ||| S:0 E:11 ||| JJ
clues  ||| S:11 E:17 ||| NNS
from  ||| S:17 E:22 ||| IN
genome  ||| S:22 E:29 ||| JJ
wide  ||| S:29 E:34 ||| JJ
transcriptome  ||| S:34 E:48 ||| JJ
analysis  ||| S:48 E:57 ||| NN
for  ||| S:57 E:61 ||| IN
exploring  ||| S:61 E:71 ||| VBG
thalidomide  ||| S:71 E:83 ||| JJ
mediated  ||| S:83 E:92 ||| JJ
anomalies  ||| S:92 E:102 ||| NN
in  ||| S:102 E:105 ||| IN
eye  ||| S:105 E:109 ||| NN
development  ||| S:109 E:121 ||| NN
of  ||| S:121 E:124 ||| IN
chick  ||| S:124 E:130 ||| JJ
embryo ||| S:130 E:136 ||| NN
:  ||| S:136 E:138 ||| :
Nitric  ||| S:138 E:145 ||| NNP
oxide  ||| S:145 E:151 ||| NN
rectifies  ||| S:151 E:161 ||| VBD
the  ||| S:161 E:165 ||| DT
thalidomide  ||| S:165 E:177 ||| JJ
mediated  ||| S:177 E:186 ||| JJ
anomalies  ||| S:186 E:196 ||| NN
by  ||| S:196 E:199 ||| IN
swinging  ||| S:199 E:208 ||| VBG
back  ||| S:208 E:213 ||| RP
the  ||| S:213 E:217 ||| DT
system  ||| S:217 E:224 ||| NN
to  ||| S:224 E:227 ||| TO
normal  ||| S:227 E:234 ||| JJ
transcriptome  ||| S:234 E:248 ||| JJ
pattern  ||| S:248 E:256 ||| NN
Thalidomide ||| S:256 E:267 ||| NNP
,  ||| S:267 E:269 ||| ,
the  ||| S:269 E:273 ||| DT
notorious  ||| S:273 E:283 ||| JJ
teratogen  ||| S:283 E:293 ||| NN
is  ||| S:293 E:296 ||| VBZ
known  ||| S:296 E:302 ||| VBN
to  ||| S:302 E:305 ||| TO
cause  ||| S:305 E:311 ||| VB
various  ||| S:311 E:319 ||| JJ
developmental  ||| S:319 E:333 ||| JJ
abnormalities ||| S:333 E:346 ||| NN
,  ||| S:346 E:348 ||| ,
among  ||| S:348 E:354 ||| IN
which  ||| S:354 E:360 ||| WDT
a  ||| S:360 E:362 ||| DT
range  ||| S:362 E:368 ||| NN
of  ||| S:368 E:371 ||| IN
eye  ||| S:371 E:375 ||| NN
deformations  ||| S:375 E:388 ||| NNS
are  ||| S:388 E:392 ||| VBP
very  ||| S:392 E:397 ||| RB
common ||| S:397 E:403 ||| JJ
.  ||| S:403 E:405 ||| .
From  ||| S:405 E:410 ||| IN
the  ||| S:410 E:414 ||| DT
clinical  ||| S:414 E:423 ||| JJ
point  ||| S:423 E:429 ||| NN
of  ||| S:429 E:432 ||| IN
view ||| S:432 E:436 ||| NN
,  ||| S:436 E:438 ||| ,
it  ||| S:438 E:441 ||| PRP
is  ||| S:441 E:444 ||| VBZ
necessary  ||| S:444 E:454 ||| JJ
to  ||| S:454 E:457 ||| TO
pinpoint  ||| S:457 E:466 ||| VB
the  ||| S:466 E:470 ||| DT
mechanisms  ||| S:470 E:481 ||| NNS
of  ||| S:481 E:484 ||| IN
teratogens  ||| S:484 E:495 ||| NNS
that  ||| S:495 E:500 ||| WDT
tune  ||| S:500 E:505 ||| VBP
the  ||| S:505 E:509 ||| DT
gene  ||| S:509 E:514 ||| NN
expression ||| S:514 E:524 ||| NN
.  ||| S:524 E:526 ||| .
However ||| S:526 E:533 ||| RB
,  ||| S:533 E:535 ||| ,
to  ||| S:535 E:538 ||| TO
our  ||| S:538 E:542 ||| PRP$
knowledge ||| S:542 E:551 ||| NN
,  ||| S:551 E:553 ||| ,
the  ||| S:553 E:557 ||| DT
molecular  ||| S:557 E:567 ||| JJ
basis  ||| S:567 E:573 ||| NN
of  ||| S:573 E:576 ||| IN
eye  ||| S:576 E:580 ||| NN
deformities  ||| S:580 E:592 ||| NN
under  ||| S:592 E:598 ||| IN
thalidomide  ||| S:598 E:610 ||| JJ
treatmenthas  ||| S:610 E:623 ||| NNS
not  ||| S:623 E:627 ||| RB
been  ||| S:627 E:632 ||| VBN
reported  ||| S:632 E:641 ||| VBN
so  ||| S:641 E:644 ||| RB
far ||| S:644 E:647 ||| RB
.  ||| S:647 E:649 ||| .
Present  ||| S:649 E:657 ||| JJ
study  ||| S:657 E:663 ||| NN
focuses  ||| S:663 E:671 ||| VBZ
on  ||| S:671 E:674 ||| IN
the  ||| S:674 E:678 ||| DT
possible  ||| S:678 E:687 ||| JJ
mechanism  ||| S:687 E:697 ||| NN
by  ||| S:697 E:700 ||| IN
which  ||| S:700 E:706 ||| WDT
thalidomide  ||| S:706 E:718 ||| VBZ
affects  ||| S:718 E:726 ||| JJ
eye  ||| S:726 E:730 ||| NN
development  ||| S:730 E:742 ||| NN
and  ||| S:742 E:746 ||| CC
the  ||| S:746 E:750 ||| DT
role  ||| S:750 E:755 ||| NN
of  ||| S:755 E:758 ||| IN
Nitric  ||| S:758 E:765 ||| NNP
Oxide  ||| S:765 E:771 ||| NNP
in  ||| S:771 E:774 ||| IN
recovering  ||| S:774 E:785 ||| VBG
thalidomide-mediated  ||| S:785 E:806 ||| JJ
anomalies  ||| S:806 E:816 ||| NN
of  ||| S:816 E:819 ||| IN
eye  ||| S:819 E:823 ||| NN
development  ||| S:823 E:835 ||| NN
using  ||| S:835 E:841 ||| VBG
chick  ||| S:841 E:847 ||| JJ
embryo  ||| S:847 E:854 ||| NN
and  ||| S:854 E:858 ||| CC
zebrafish  ||| S:858 E:868 ||| JJ
models  ||| S:868 E:875 ||| NNS
with  ||| S:875 E:880 ||| IN
transcriptome  ||| S:880 E:894 ||| JJ
analysis ||| S:894 E:902 ||| NN
.  ||| S:902 E:904 ||| .
Transcriptome  ||| S:904 E:918 ||| JJ
analysis  ||| S:918 E:927 ||| NN
showed  ||| S:927 E:934 ||| VBD
that  ||| S:934 E:939 ||| IN
403  ||| S:939 E:943 ||| CD
genes  ||| S:943 E:949 ||| NNS
were  ||| S:949 E:954 ||| VBD
up-regulated  ||| S:954 E:967 ||| JJ
and  ||| S:967 E:971 ||| CC
223  ||| S:971 E:975 ||| CD
genes  ||| S:975 E:981 ||| NNS
were  ||| S:981 E:986 ||| VBD
down-regulated  ||| S:986 E:1001 ||| JJ
significantly  ||| S:1001 E:1015 ||| RB
in  ||| S:1015 E:1018 ||| IN
thalidomide  ||| S:1018 E:1030 ||| JJ
pre-treated  ||| S:1030 E:1042 ||| JJ
embryos.  ||| S:1042 E:1051 ||| CD
8 ||| S:1051 E:1052 ||| CD
%  ||| S:1052 E:1054 ||| NN
of  ||| S:1054 E:1057 ||| IN
the  ||| S:1057 E:1061 ||| DT
significantly  ||| S:1061 E:1075 ||| RB
modulated  ||| S:1075 E:1085 ||| JJ
genes  ||| S:1085 E:1091 ||| NNS
have  ||| S:1091 E:1096 ||| VBP
been  ||| S:1096 E:1101 ||| VBN
implicated  ||| S:1101 E:1112 ||| VBN
in  ||| S:1112 E:1115 ||| IN
eye  ||| S:1115 E:1119 ||| NN
development  ||| S:1119 E:1131 ||| NN
including  ||| S:1131 E:1141 ||| VBG
Pax6 ||| S:1141 E:1145 ||| NNP
,  ||| S:1145 E:1147 ||| ,
OTX2 ||| S:1147 E:1151 ||| NNP
,  ||| S:1151 E:1153 ||| ,
Dkk1  ||| S:1153 E:1158 ||| NNP
and  ||| S:1158 E:1162 ||| CC
Shh ||| S:1162 E:1165 ||| NNP
.  ||| S:1165 E:1167 ||| .
A  ||| S:1167 E:1169 ||| DT
wide  ||| S:1169 E:1174 ||| JJ
range  ||| S:1174 E:1180 ||| NN
of  ||| S:1180 E:1183 ||| IN
biological  ||| S:1183 E:1194 ||| JJ
process  ||| S:1194 E:1202 ||| NN
and  ||| S:1202 E:1206 ||| CC
molecular  ||| S:1206 E:1216 ||| JJ
function  ||| S:1216 E:1225 ||| NN
was  ||| S:1225 E:1229 ||| VBD
affected  ||| S:1229 E:1238 ||| VBN
by  ||| S:1238 E:1241 ||| IN
thalidomide  ||| S:1241 E:1253 ||| JJ
exposure ||| S:1253 E:1261 ||| NN
.  ||| S:1261 E:1263 ||| .
Biological  ||| S:1263 E:1274 ||| NNP
Processes  ||| S:1274 E:1284 ||| NNP
including  ||| S:1284 E:1294 ||| VBG
structural  ||| S:1294 E:1305 ||| JJ
constituent  ||| S:1305 E:1317 ||| NN
of  ||| S:1317 E:1320 ||| IN
eye  ||| S:1320 E:1324 ||| NN
lens  ||| S:1324 E:1329 ||| NN
and  ||| S:1329 E:1333 ||| CC
Molecular  ||| S:1333 E:1343 ||| NNP
functions  ||| S:1343 E:1353 ||| NNS
such  ||| S:1353 E:1358 ||| JJ
as  ||| S:1358 E:1361 ||| IN
visual  ||| S:1361 E:1368 ||| JJ
perception  ||| S:1368 E:1379 ||| NN
and  ||| S:1379 E:1383 ||| CC
retinal  ||| S:1383 E:1391 ||| JJ
metabolic  ||| S:1391 E:1401 ||| JJ
process  ||| S:1401 E:1409 ||| NN
formed  ||| S:1409 E:1416 ||| VBD
strong  ||| S:1416 E:1423 ||| JJ
annotation  ||| S:1423 E:1434 ||| NNS
clustersindicating  ||| S:1434 E:1453 ||| VBP
the  ||| S:1453 E:1457 ||| DT
adverse  ||| S:1457 E:1465 ||| JJ
effects  ||| S:1465 E:1473 ||| NNS
of  ||| S:1473 E:1476 ||| IN
thalidomide  ||| S:1476 E:1488 ||| NN
on  ||| S:1488 E:1491 ||| IN
eye  ||| S:1491 E:1495 ||| NN
development  ||| S:1495 E:1507 ||| NN
and  ||| S:1507 E:1511 ||| CC
function ||| S:1511 E:1519 ||| NN
.  ||| S:1519 E:1521 ||| .
Here ||| S:1521 E:1525 ||| RB
,  ||| S:1525 E:1527 ||| ,
we  ||| S:1527 E:1530 ||| PRP
have  ||| S:1530 E:1535 ||| VBP
discussed  ||| S:1535 E:1545 ||| VBN
the  ||| S:1545 E:1549 ||| DT
whole  ||| S:1549 E:1555 ||| JJ
embryo  ||| S:1555 E:1562 ||| NN
transcriptome  ||| S:1562 E:1576 ||| NN
with  ||| S:1576 E:1581 ||| IN
the  ||| S:1581 E:1585 ||| DT
expression  ||| S:1585 E:1596 ||| NN
of  ||| S:1596 E:1599 ||| IN
PAX6 ||| S:1599 E:1603 ||| NNP
,  ||| S:1603 E:1605 ||| ,
SOX2 ||| S:1605 E:1609 ||| NNP
,  ||| S:1609 E:1611 ||| ,
and  ||| S:1611 E:1615 ||| CC
CRYAAgenes  ||| S:1615 E:1626 ||| JJ
from  ||| S:1626 E:1631 ||| IN
developing  ||| S:1631 E:1642 ||| VBG
eyes ||| S:1642 E:1646 ||| NNS
.  ||| S:1646 E:1648 ||| .
Our  ||| S:1648 E:1652 ||| PRP$
experimental  ||| S:1652 E:1665 ||| JJ
data  ||| S:1665 E:1670 ||| NNS
showing  ||| S:1670 E:1678 ||| VBG
structural  ||| S:1678 E:1689 ||| JJ
and  ||| S:1689 E:1693 ||| CC
functional  ||| S:1693 E:1704 ||| JJ
aspects  ||| S:1704 E:1712 ||| NNS
includingeye  ||| S:1712 E:1725 ||| JJ
size ||| S:1725 E:1729 ||| NN
,  ||| S:1729 E:1731 ||| ,
lens  ||| S:1731 E:1736 ||| NN
transparency  ||| S:1736 E:1749 ||| NNS
and  ||| S:1749 E:1753 ||| CC
optic  ||| S:1753 E:1759 ||| JJ
nerve  ||| S:1759 E:1765 ||| NN
activity  ||| S:1765 E:1774 ||| NN
and  ||| S:1774 E:1778 ||| CC
bioinformatics  ||| S:1778 E:1793 ||| JJ
analyses  ||| S:1793 E:1802 ||| NNS
of  ||| S:1802 E:1805 ||| IN
transcriptome  ||| S:1805 E:1819 ||| NNS
suggest  ||| S:1819 E:1827 ||| VBP
that  ||| S:1827 E:1832 ||| IN
NO  ||| S:1832 E:1835 ||| DT
could  ||| S:1835 E:1841 ||| MD
partially  ||| S:1841 E:1851 ||| RB
protect  ||| S:1851 E:1859 ||| VB
thalidomide  ||| S:1859 E:1871 ||| VBN
treated  ||| S:1871 E:1879 ||| VBN
embryos  ||| S:1879 E:1887 ||| VBN
from  ||| S:1887 E:1892 ||| IN
its  ||| S:1892 E:1896 ||| PRP$
devastating  ||| S:1896 E:1908 ||| JJ
effects  ||| S:1908 E:1916 ||| NNS
on  ||| S:1916 E:1919 ||| IN
eye  ||| S:1919 E:1923 ||| NN
development  ||| S:1923 E:1935 ||| NN
and  ||| S:1935 E:1939 ||| CC
function ||| S:1939 E:1947 ||| NN
.  ||| S:1947 E:1949 ||| .
